The U.S. Food and Drug Administration rejected the application for ivonescimab, a lung-cancer drug developed by China’s Akeso. Summit Therapeutics, which holds exclusive global development and commercialization rights, said the drug had not established “substantial evidence of effectiveness”; the FDA told the company it must show the drug helps patients live longer. Akeso shares fell as much as 31.8% Monday morning.
3 reports from 3 publishers confirmed as covering this specific event.
Reporting from 3 identified publishers across this event arc.
These publishers contributed reporting to the broader event history. Not every source addresses the specific development described above.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Page 464 of 22954
Same format. Every time.
Continue reading — sign in or create a free account with